The following highlights spotlight several standout abstracts presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting, covering topics such as the effects of extended overnight fasting, the incidence of congenital heart defects in the offspring of females diagnosed with pregestational diabetes, and telehealth for the metabolic control of Type 1 diabetes.

AFTER 2 years of virtual meetings, the 58th European Association for the Study of Diabetes (EASD) Annual Meeting took a hybrid form, with 7,716 participants onsite in Stockholm, Sweden, as well as 3,291 participants online. The programme of the congress was developed to cover the most recent developments and breaking news relating to diabetes research, covering the latest innovations and developments in the treatment of Type 1 and Type 2 diabetes (T2D), as well as their complications.

This symposium took place at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The first speaker was John L. Sievenpiper, who discussed the pathophysiology of postprandial hyperglycaemia and how it may impact the risk of cardiovascular disease (CVD), peripheral vascular disease, insulin resistance, and other comorbidities in patients with Type 2 diabetes (T2D).

TDHS is characterised by symptoms ranging from a localised cellulitis to gangrene and sepsis. This article reports on the importance of timely intervention and patient education.

THIS year’s European Association for the Study of Diabetes (EASD) Annual Meeting 2022 was a hybrid congress, which focused on inclusion and interaction within the global diabetes community whether participants attended in person in Stockholm, Sweden, or virtually.

A new review has outlined 20 recommendations for how the UK can become a world leader in cannabinoid innovation. But is it possible?

Pfizer plans to file for approval for its RSV vaccine for infants by the end of 2022 after achieving positive Phase 3 results.

The pharmaceutical industry has been trying to refine, reduce and replace animal testing for some time, but animal rights activists argue progress is too incremental.

The overturning of Roe v. Wade is impacting access to medical abortion, but in what ways is pharma trying to help?